Literature DB >> 10768341

Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy.

L A Yannuzzi1, K B Freund, M Goldbaum, B Scassellati-Sforzolini, D R Guyer, R F Spaide, D Maberley, D W Wong, J S Slakter, J A Sorenson, Y L Fisher, D A Orlock.   

Abstract

OBJECTIVE: To differentiate polypoidal choroidal vasculopathy (PCV) from central serous chorioretinopathy (CSC).
DESIGN: A retrospective, observational case series. PARTICIPANTS: Thirteen patients originally diagnosed with CSC proved to have PCV after more extensive evaluation and follow-up.
METHODS: A clinical and angiographic review of patients with manifestations of CSC, including macular detachment. MAIN OUTCOME MEASURES: Demographic data, funduscopic examination, and fluorescein and indocyanine green (ICG) angiographic findings.
RESULTS: Thirteen patients initially suspected of having CSC were ultimately diagnosed as having PCV. These eyes had exudative macular detachments secondary to a small caliber, polypoidal choroidal vascular abnormality or so-called polypoidal choroidal neovascularization. The clinical manifestations in the fundus varied. They included multiple, variably sized serous pigment epithelial detachments, neurosensory retinal detachment, lipid deposition, patchy atrophy of the pigment epithelium and indistinct staining from decompensation of the posterior blood-retinal barrier on fluorescein angiography. In reality, the suspected PEDs proved to be polypoidal lesions of PCV when imaged with ICG angiography.
CONCLUSIONS: The clinical diagnosis of CSC or PCV generally poses little challenge to the experienced retinal specialist. However, in CSC with persistent and/or recurrent exudation, a myriad of retinal pigment epithelial changes may evolve that make it difficult to differentiate these two entities. In such patients, ICG angiography is useful in differentiating CSC from PCV. An accurate clinical diagnosis is important since each of these entities, CSC and PCV, may differ in terms of their risk factors, natural course, and visual prognosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768341     DOI: 10.1016/s0161-6420(99)00173-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  34 in total

1.  Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.

Authors:  Shiu Ting Mak; Albert Chak-ming Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-10       Impact factor: 3.117

2.  Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration.

Authors:  Miki Sawa; Eiji Iwata; Kohei Ishikawa; Fumi Gomi; Kohji Nishida; Hiroko Terasaki
Journal:  Jpn J Ophthalmol       Date:  2012-06-09       Impact factor: 2.447

3.  The origins of polypoidal choroidal vasculopathy.

Authors:  M Yuzawa; R Mori; A Kawamura
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

4.  [Visual loss after pars plana vitrectomy with membrane peeling].

Authors:  M Schmidt; N Schrage; C Clemens; N Eter
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

5.  Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Hideki Koizumi; Tetsuya Yamagishi; Taizo Yamazaki; Ryo Kawasaki; Shigeru Kinoshita
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-28       Impact factor: 3.117

6.  Detecting abnormalities in choroidal vasculature in a mouse model of age-related macular degeneration by time-course indocyanine green angiography.

Authors:  Sandeep Kumar; Zachary Berriochoa; Alex D Jones; Yingbin Fu
Journal:  J Vis Exp       Date:  2014-02-19       Impact factor: 1.355

Review 7.  The Biology of Ciliary Dynamics.

Authors:  Kuo-Shun Hsu; Jen-Zen Chuang; Ching-Hwa Sung
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-04-03       Impact factor: 10.005

8.  Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome.

Authors:  Young Suk Chang; Jae Hui Kim; Jong Woo Kim; Tae Gon Lee; Chul Gu Kim; Sung Won Cho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-19       Impact factor: 3.117

9.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

10.  One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.

Authors:  Hidetaka Matsumoto; Ryo Mukai; Yuka Kikuchi; Masahiro Morimoto; Hideo Akiyama
Journal:  Jpn J Ophthalmol       Date:  2020-02-03       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.